RPC
BMY.RT

Rossmore Private Capital’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Rossmore Private Capital’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-15,222
Closed -$11K – 217
2020
Q4 		$11K Sell
15,222
-508
-3% -$1.08K ﹤0.01% 200
2020
Q3 		$35K Buy
15,730
+2,078
+15% +$5.93K 0.01% 191
2020
Q2 		$49K Buy
13,652
+2,183
+19% +$7.88K 0.01% 168
2020
Q1 		$44K Buy
+11,469
New +$37.8K 0.02% 147

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Rossmore Private Capital's BMY.RT Position: Q1 2021 in Review

Rossmore Private Capital sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 15,222 shares — an estimated $11K sold.

Rossmore Private Capital first reported a position in BMY.RT in Q1 2020 and held it in 4 quarters. The position peaked at $49K in Q2 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Rossmore Private Capital reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Rossmore Private Capital sold 15,222 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $11K.
  • Rossmore Private Capital first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q1 2020 and held it in 4 quarters.
  • Rossmore Private Capital's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $49K in Q2 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Rossmore Private Capital's 13F filing for Q1 2021, filed 10 May 2021.